adalimumab vs obefazimod

Same indication, different mechanisms: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

adalimumab: TNF-alpha · obefazimod: miR-124 · full Ulcerative Colitis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Partial signal

NCT00385736 · Phase 3 · completed

Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.

Next expected readout: September 2027 · NCT06257875 (registry estimate)

Reported efficacy

Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)

Result source: NCT00408629

obefazimod

Developed by Abivax

Phase 3 in Ulcerative ColitisSmall molecule (oral miR-124 enhancer)
Reliable signal

NCT05507203 · Phase 3 · completed

The trial was randomized, blinded, and placebo-controlled with a hard clinical/endoscopic primary endpoint (clinical remission), and both the 25 mg and 50 mg doses produced significantly higher remission rates than placebo (23.8% and 21.7% vs 2.5%, both P<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2028 · NCT05177835 (registry estimate)

Reported efficacy

Rate of subjects in clinical remission at Week 44; Number and percentage of all treatment-emergent adverse events (TEAEs) (Week 44); Number and percentage of all serious adverse events (SAEs) (Week 44); Number and percentage of all causally related TEAEs/SAEs (Week 44): ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001 (met)

Result source: NCT05535946

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabobefazimod
Clinical remission (induction)10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
17.5% vs 12.5%+5 vs placebo50 mg · wk 8 · n 63NCT03760003
10 other results
  • 20% vs 13% 50 mg · wk 16 · n 30 · Phase 2 · secondary NCT03760003
  • 26.2% vs 12.5% 25 mg · wk 8 · n 61 · Phase 2 · secondary NCT03760003
  • 24.3% vs 13% 25 mg · wk 16 · n 37 · Phase 2 · secondary NCT03760003
  • 25% vs 12.5% 100 mg · wk 8 · n 64 · Phase 2 · secondary NCT03760003
  • 22.6% vs 13% 100 mg · wk 16 · n 31 · Phase 2 · secondary NCT03760003
  • 11.1% vs 35% wk 8 · n 9 · Phase 2 · secondary NCT03093259
  • 21.7% vs 2.5% 50 mg · wk 8 · Phase 3 · primary NCT05507203
  • 19.8% vs 6.3% 50 mg · wk 8 · Phase 3 · primary NCT05507216
  • 23.8% vs 2.5% 25 mg · wk 8 · Phase 3 · primary NCT05507203
  • 11.3% vs 6.3% 25 mg · wk 8 · Phase 3 · primary NCT05507216
Clinical remission (maintenance)20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
—Trial running · NCT05535946
Clinical response (induction)50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
58.7% vs 34.4%+24.3 vs placebo50 mg · wk 8 · n 63NCT03760003
5 other results
  • 66.7% vs 43.5% 50 mg · wk 16 · n 30 · Phase 2 · secondary NCT03760003
  • 62.3% vs 34.4% 25 mg · wk 8 · n 61 · Phase 2 · secondary NCT03760003
  • 67.6% vs 43.5% 25 mg · wk 16 · n 37 · Phase 2 · secondary NCT03760003
  • 50% vs 34.4% 100 mg · wk 8 · n 64 · Phase 2 · secondary NCT03760003
  • 61.3% vs 43.5% 100 mg · wk 16 · n 31 · Phase 2 · secondary NCT03760003
Endoscopic improvement (induction)44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Trial running · NCT05535946
Corticosteroid-free remission (maintenance)13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
—Trial running · NCT05535946

Clinical remission (induction)

adalimumab
10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
obefazimod
17.5% vs 12.5%+5 vs placebo50 mg · wk 8 · n 63NCT03760003
10 other results
  • 20% vs 13% 50 mg · wk 16 · n 30 · Phase 2 · secondary NCT03760003
  • 26.2% vs 12.5% 25 mg · wk 8 · n 61 · Phase 2 · secondary NCT03760003
  • 24.3% vs 13% 25 mg · wk 16 · n 37 · Phase 2 · secondary NCT03760003
  • 25% vs 12.5% 100 mg · wk 8 · n 64 · Phase 2 · secondary NCT03760003
  • 22.6% vs 13% 100 mg · wk 16 · n 31 · Phase 2 · secondary NCT03760003
  • 11.1% vs 35% wk 8 · n 9 · Phase 2 · secondary NCT03093259
  • 21.7% vs 2.5% 50 mg · wk 8 · Phase 3 · primary NCT05507203
  • 19.8% vs 6.3% 50 mg · wk 8 · Phase 3 · primary NCT05507216
  • 23.8% vs 2.5% 25 mg · wk 8 · Phase 3 · primary NCT05507203
  • 11.3% vs 6.3% 25 mg · wk 8 · Phase 3 · primary NCT05507216

Clinical remission (maintenance)

adalimumab
20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
obefazimod
—Trial running · NCT05535946

Clinical response (induction)

adalimumab
50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
obefazimod
58.7% vs 34.4%+24.3 vs placebo50 mg · wk 8 · n 63NCT03760003
5 other results
  • 66.7% vs 43.5% 50 mg · wk 16 · n 30 · Phase 2 · secondary NCT03760003
  • 62.3% vs 34.4% 25 mg · wk 8 · n 61 · Phase 2 · secondary NCT03760003
  • 67.6% vs 43.5% 25 mg · wk 16 · n 37 · Phase 2 · secondary NCT03760003
  • 50% vs 34.4% 100 mg · wk 8 · n 64 · Phase 2 · secondary NCT03760003
  • 61.3% vs 43.5% 100 mg · wk 16 · n 31 · Phase 2 · secondary NCT03760003

Endoscopic improvement (induction)

adalimumab
44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
obefazimod
—Trial running · NCT05535946

Corticosteroid-free remission (maintenance)

adalimumab
13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
obefazimod
—Trial running · NCT05535946
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. adalimumab: 11 of 11 rows · obefazimod: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
obefazimod
Rows use multiple source trials
Clinical Remission
responder rate · % of participants
No placebo or comparator arm
61.2% (n=585) @ 48wk40 mg EOW/EWa,b,c
NCT00573794 · Phase 3 · monotherapy
54.8% (n=217) @ 48wk*50mga,b,c
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 119 Participants as posted
Endoscopic Improvement
event count · % of participants
Induction
46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40d,a,b,c
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more dose
37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
39.6% (n=53) vs 13.6% (n=59) placebo @ 8wk*50 mgd,a,b,c
NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
show 2 more doses
34.5% (n=58) vs 13.6% (n=59) placebo @ 8wk*25 mg
NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 20 Participants as posted
44.4% (n=54) vs 13.6% (n=59) placebo @ 8wk*100 mg
NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted
Partial Mayo
absolute change · score
No placebo or comparator arm
-2 score @ 388wk40 mg EOW/EWa,b,c,e
NCT00573794 · Phase 3 · monotherapy
-2.2 scorea,b,c,e
NCT03368118 · Phase 2 · registry result, not featured evidence
Rectal Bleeding Subscore 0 1
event count · % of participants
Induction
77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40d,a,b,c
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more dose
70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
72.1% (n=61) vs 51.6% (n=64) placebo @ 8wk*50 mgd,a,b,c
NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 44 Participants as posted
show 2 more doses
76.7% (n=60) vs 51.6% (n=64) placebo @ 8wk*25 mg
NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 46 Participants as posted
76.2% (n=63) vs 51.6% (n=64) placebo @ 8wk*100 mg
NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 48 Participants as posted
SF-36 MCS
absolute change · score
No placebo or comparator arm
-7.3 score @ 388wk40 mg EOW/EWa,b,c,e
NCT00573794 · Phase 3 · monotherapy
6.38 scorea,b,c,e
NCT03368118 · Phase 2 · registry result, not featured evidence
SF-36 PCS
absolute change · score
No placebo or comparator arm
8.4 score @ 388wk40 mg EOW/EWa,b,c,e
NCT00573794 · Phase 3 · monotherapy
4.82 scorea,b,c,e
NCT03368118 · Phase 2 · registry result, not featured evidence
Total Mayo
absolute change · score
No placebo or comparator arm
-2 score @ 388wk40 mg EOW/EWa,b,c,e
NCT00573794 · Phase 3 · monotherapy
-3 scorea,b,c,e
NCT03368118 · Phase 2 · registry result, not featured evidence
Dropout rate
6.9%160/80/40f
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
9.2%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.6%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52.5%
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
10.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.4%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
34.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
24.4%50mgg
NCT04023396 · Phase 2 · registry result, not featured evidence
show 9 more results
50%
NCT03368118 · Phase 2 · registry result, not featured evidence
15.9%50 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—50 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
7.9%25 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—25mg
NCT03760003 · Phase 2 · registry result, not featured evidence
15.6%100 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—100mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—ABX464
NCT03093259 · Phase 2 · registry result, not featured evidence
8.7%ABX464 Treatment Arm
NCT03093259 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%160/80/40f
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
4.6%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
14.3%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
7.4%50mgg
NCT04023396 · Phase 2 · registry result, not featured evidence
show 9 more results
—
NCT03368118 · Phase 2 · registry result, not featured evidence
—50 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—50 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—25 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—25mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—100mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—ABX464
NCT03093259 · Phase 2 · registry result, not featured evidence
4.3%ABX464 Treatment Arm
NCT03093259 · Phase 2 · registry result, not featured evidence
Serious AEs
4%160/80/40f
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
3.8%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
12.1%Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.1%
NCT02632175 · Phase 3 · monotherapy
7.8%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
5.6%open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.6%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
13.9%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.2%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.8%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
5%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.6%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.8%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
9.9%Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
11.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.1%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.5%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
8.3%50mgg
NCT04023396 · Phase 2 · registry result, not featured evidence
show 9 more results
13.6%
NCT03368118 · Phase 2 · registry result, not featured evidence
—50 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
6.3%50 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—25 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
1.6%25mg
NCT03760003 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03760003 · Phase 2 · registry result, not featured evidence
6.3%100mg
NCT03760003 · Phase 2 · registry result, not featured evidence
0%ABX464
NCT03093259 · Phase 2 · registry result, not featured evidence
—ABX464 Treatment Arm
NCT03093259 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
160/80/40f
colitis ulcerative 4% (placebo 3.6%)
fatigue 4% (placebo 2.2%)
headache 3.1% (placebo 7.2%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 17 more results
80/40
headache 6.9% (placebo 7.2%)
colitis ulcerative 5.4% (placebo 3.6%)
nasopharyngitis 4.6% (placebo 1.8%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 17.5% (placebo 10.4%)
colitis ulcerative 16.3% (placebo 22.3%)
headache 8.6% (placebo 14.2%)
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 33.9%
upper respiratory tract infection 27.1%
nasopharyngitis 22%
NCT02632175 · Phase 3 · monotherapy
high dose
headache 9.8% (placebo 16.7%)
anaemia 5.9% (placebo 8.3%)
nausea 5.9% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
open-label high dose
headache 22.2% (placebo 16.7%)
abdominal pain 11.1% (placebo 8.3%)
oropharyngeal pain 11.1% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 12.5% (placebo 16.7%)
colitis ulcerative 6.3% (placebo 16.7%)
nasopharyngitis 6.3% (placebo 8.3%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
high dose
colitis ulcerative 11.1% (placebo 16.7%)
nasopharyngitis 11.1% (placebo 8.3%)
upper respiratory tract infection 11.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 18.2% (placebo 16.7%)
c-reactive protein increased 9.1% (placebo 0%)
colitis ulcerative 9.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 8.4%
nasopharyngitis 5.1%
arthralgia 3.1%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 6.1%
colitis ulcerative 5.3%
nasopharyngitis 4.2%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 13.4%
nasopharyngitis 13.1%
arthralgia 6.6%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 17.4%
nasopharyngitis 13.6%
arthralgia 6.7%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 15.2%
nasopharyngitis 7.3%
upper respiratory tract infection 6%
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
40 mg EOW/EW
colitis ulcerative 30.4%
viral upper respiratory tract infection 19.4%
arthralgia 10.5%
NCT00573794 · Phase 3 · monotherapy
160 mg/80 mg
nasopharyngitis 33.3% (placebo 21.9%)
iron deficiency anaemia 8.9% (placebo 7.3%)
headache 7.8% (placebo 6.3%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
80 mg/40 mg
nasopharyngitis 21.8% (placebo 21.9%)
injection site reaction 8% (placebo 2.1%)
dental caries 6.9% (placebo 5.2%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 13.2%
headache 13%
nasopharyngitis 8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50mgg
covid-19 14.3%
headache 11.5%
colitis ulcerative 7.8%
NCT04023396 · Phase 2 · registry result, not featured evidence
show 5 more results
colitis ulcerative 31.8%
abdominal pain 22.7%
nasopharyngitis 22.7%
NCT03368118 · Phase 2 · registry result, not featured evidence
50 mg
headache 30.2% (placebo 7.8%)
nausea 6.3% (placebo 6.3%)
abdominal pain upper 4.8% (placebo 0%)
NCT03760003 · Phase 2 · registry result, not featured evidence
25mg
headache 21% (placebo 7.8%)
nausea 8.1% (placebo 6.3%)
abdominal pain upper 4.8% (placebo 0%)
NCT03760003 · Phase 2 · registry result, not featured evidence
100mg
headache 42.2% (placebo 7.8%)
nausea 14.1% (placebo 6.3%)
arthralgia 7.8% (placebo 4.7%)
NCT03760003 · Phase 2 · registry result, not featured evidence
abdominal pain 17.4% (placebo 11.1%)
headache 17.4% (placebo 0%)
abdominal pain upper 13% (placebo 0%)
NCT03093259 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for 2 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Remission 20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 14 more results
17.8% (n=90) vs 8.3% (n=96) placebo @ 32wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.2% (n=87) vs 8.3% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.3% (n=248) vs 8.5% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
29% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.3% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.5% (n=22) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
44% (n=25) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical Remission 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 37.8% (n=90) vs 20.8% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=87) vs 20.8% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 31.1% (n=90) vs 21.9% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
28.9% (n=90) vs 15.6% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.6% (n=87) vs 21.9% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
28.7% (n=87) vs 15.6% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
25% (n=248) vs 15.4% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
38.7% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.6% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
36.4% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
48.6% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Mucosal Healing 18.5% (n=248) vs 10.6% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Corticosteroid-free Clinical Remission 13.3% (n=150) vs 5.7% (n=140) placebo @ 52wk160/80/40
responder rate · % of participants
Maintenance
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
show 5 more results
13.3% (n=150) vs 5.7% (n=140) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
30.8% (n=13) vs 40% (n=5) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
31.3% (n=16) vs 40% (n=5) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7% (n=15) vs 40% (n=5) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
35.3% (n=17) vs 40% (n=5) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
PGA 0-1 46% (n=248) vs 37.4% (n=246) placebo @ 8wk160/80/40
responder rate · % of participants
Induction
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 42 further endpoints in the CSV export.

obefazimod

Clinical Response 81.6% (n=217) @ 48wk50mg
responder rate · % of participants
No placebo or comparator arm
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 177 Participants as posted
show 2 more results
72.8% (n=217) @ 96wk*50mg
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 158 Participants as posted
50% (n=22) @ 208wk*
NCT03368118 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
Endoscopic Improvement 61.3% (n=217) @ 48wk50mg
event count · % of participants
No placebo or comparator arm
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted
show 2 more results
59% (n=217) @ 96wk*50mg
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 128 Participants as posted
40.9% (n=22) @ 208wk*
NCT03368118 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
Endoscopic Remission 33.2% (n=217) @ 48wk50mg
responder rate · % of participants
No placebo or comparator arm
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 72 Participants as posted
show 2 more results
35.9% (n=217) @ 96wk*50mg
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 78 Participants as posted
27.3% (n=22) @ 208wk*
NCT03368118 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
Sustained Endoscopic Improvement 24.4% (n=217) @ 48wk50mg
event count · % of participants
No placebo or comparator arm
Sustained endoscopic improvement at Week 48
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 53 Participants as posted
Sustained Endoscopic Remission 6% (n=217) @ 48wk50mg
responder rate · % of participants
No placebo or comparator arm
Sustained endoscopic remission at Week 48
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
Sustained Endoscopic Improvement 23% (n=217) @ 96wk50mg
event count · % of participants
No placebo or comparator arm
Sustained endoscopic improvement at Week 96
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 50 Participants as posted
Sustained Endoscopic Remission 5.1% (n=217) @ 96wk50mg
responder rate · % of participants
No placebo or comparator arm
Sustained endoscopic remission at Week 96
NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
MMS 1.8 score @ 48wk50mg
absolute change · score
No placebo or comparator arm
MMS Week 48
NCT04023396 · Phase 2 · registry result, not featured evidence
MMS 1.5 score @ 96wk50mg
absolute change · score
No placebo or comparator arm
MMS Week 96
NCT04023396 · Phase 2 · registry result, not featured evidence
Partial Mayo 1.4 score @ 4wk50mg
absolute change · score
No placebo or comparator arm
pMMS Week 4
NCT04023396 · Phase 2 · registry result, not featured evidence
Partial Mayo 1.4 score @ 8wk50mg
absolute change · score
No placebo or comparator arm
pMMS Week 8
NCT04023396 · Phase 2 · registry result, not featured evidence
Partial Mayo 1.3 score @ 12wk50mg
absolute change · score
No placebo or comparator arm
pMMS Week 12
NCT04023396 · Phase 2 · registry result, not featured evidence

+ 59 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · obefazimod's landscape